KRAS (STM: > 70%; GCT: 16%) and KIT (STM: 30%; GCT: 14%) were the most amplified or missense mutated genes in the GCT cohort with the majority being mutated in seminomas (Fig. S1B). The gene discussed is KRAS; the disease is granular cell tumor.